The role of peroxisome proliferator-activated receptors in carcinogenesis and chemoprevention (original) (raw)

• Schupp, M. & Lazar, M. A. Endogenous ligands for nuclear receptors: digging deeper. J. Biol. Chem. 285, 40409–40415 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Shi, Y., Hon, M. & Evans, R. M. The peroxisome proliferator-activated receptor δ, an integrator of transcriptional repression and nuclear receptor signaling. Proc. Natl Acad. Sci. USA 99, 2613–2618 (2002).
  Article CAS PubMed PubMed Central Google Scholar
• Adhikary, T. et al. Genomewide analyses define different modes of transcriptional regulation by peroxisome proliferator-activated receptor-β/δ (PPARβ/δ). PLoS ONE 6, e16344 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Borland, M. G. et al. Stable over-expression of PPARβ/δ and PPARγ to examine receptor signaling in human HaCaT keratinocytes. Cell. Signal. 23, 2039–2050 (2011). This study critically examined possible mechanisms of PPARβ/δ-dependent regulation, including whether retinoic acid activates PPARβ/δ, whether PPARβ/δ represses PPARγ activity and how PPARβ/δ regulates apoptosis and inflammatory cytokine expression following exposure to ultraviolet light.
  Article CAS PubMed PubMed Central Google Scholar
• Marin, H. E. et al. Ligand activation of peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) inhibits colon carcinogenesis. Cancer Res. 66, 4394–4401 (2006).
  Article CAS PubMed Google Scholar
• Matsusue, K., Peters, J. M. & Gonzalez, F. J. PPARβ/δ potentiates PPARγ-stimulated adipocyte differentiation. FASEB J. 18, 1477–1479 (2004).
  Article CAS PubMed Google Scholar
• Peters, J. M., Aoyama, T., Burns, A. M. & Gonzalez, F. J. Bezafibrate is a dual ligand for PPARα and PPARβ: studies using null mice. Biochim. Biophys. Acta 1632, 80–89 (2003).
  Article CAS PubMed Google Scholar
• Kilgore, K. S. & Billin, A. N. PPARβ/δ ligands as modulators of the inflammatory response. Curr. Opin. Investig. Drugs 9, 463–469 (2008).
  CAS PubMed Google Scholar
• Peters, J. M., Foreman, J. E. & Gonzalez, F. J. Dissecting the role of peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) in colon, breast and lung carcinogenesis. Cancer Metastasis Rev. 30, 619–640 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Peters, J. M. & Gonzalez, F. J. Sorting out the functional role(s) of peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) in cell proliferation and cancer. Biochim. Biophys. Acta 1796, 230–241 (2009).
  CAS PubMed PubMed Central Google Scholar
• Peters, J. M., Hollingshead, H. E. & Gonzalez, F. J. Role of peroxisome-proliferator-activated receptor β/δ (PPARβ/δ) in gastrointestinal tract function and disease. Clin. Sci. 115, 107–127 (2008).
  Article CAS Google Scholar
• Peters, J. M., Morales, J. L. & Gonzales, F. J. Modulation of gastrointestinal inflammation and colorectal tumorigenesis by peroxisome proliferator-activated receptor-β/δ (PPARβ/δ). Drug Discov. Today Dis. Mech. 29 Nov 2011 (doi: 10.1016/j.ddmec.2011.11.002).
  Article CAS PubMed Google Scholar
• Varga, T., Czimmerer, Z. & Nagy, L. PPARs are a unique set of fatty acid regulated transcription factors controlling both lipid metabolism and inflammation. Biochim. Biophys. Acta 1812, 1007–1022 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Pascual, G. et al. A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-γ. Nature 437, 759–763 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Straus, D. S. & Glass, C. K. Anti-inflammatory actions of PPAR ligands: new insights on cellular and molecular mechanisms. Trends Immunol. 28, 551–558 (2007). A good review of the literature describing mechanisms of trans-repression by PPARs.
  Article CAS PubMed Google Scholar
• Choi, J. H. et al. Antidiabetic actions of a non-agonist PPARγ ligand blocking Cdk5-mediated phosphorylation. Nature 477, 477–481 (2011). This study demonstrated the feasibility of targeting PPARγ with a non-agonist to elicit anti-diabetic activity without causing the negative side effects that are associated with some PPARγ agonists.
  Article CAS PubMed PubMed Central Google Scholar
• Issemann, I. & Green, S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 347, 645–650 (1990). This study describes the cloning and characterization of PPARα, the first of the three PPARs to be identified.
  Article CAS PubMed Google Scholar
• Escher, P. et al. Rat PPARs: quantitative analysis in adult rat tissues and regulation in fasting and refeeding. Endocrinology 142, 4195–4202 (2001).
  Article CAS PubMed Google Scholar
• Pyper, S. R., Viswakarma, N., Yu, S. & Reddy, J. K. PPARα: energy combustion, hypolipidemia, inflammation and cancer. Nucl. Recept Signal. 8, e002 (2010).
  Article PubMed PubMed Central CAS Google Scholar
• Mandard, S., Muller, M. & Kersten, S. Peroxisome proliferator-activated receptor α target genes. Cell. Mol. Life Sci. 61, 393–416 (2004). A useful resource listing PPARα target genes and corresponding references.
  Article CAS PubMed Google Scholar
• Kersten, S. et al. The peroxisome proliferator-activated receptor α regulates amino acid metabolism. FASEB J. 15, 1971–1978 (2001).
  Article CAS PubMed Google Scholar
• Guerre-Millo, M. et al. Peroxisome Proliferator-activated Receptorα activators improve insulin sensitivity and reduce adiposity. J. Biol. Chem. 275, 16638–16642 (2000).
  Article CAS PubMed Google Scholar
• Uhlen, M. et al. Towards a knowledge-based Human Protein Atlas. Nature Biotech. 28, 1248–1250 (2010).
  Article CAS Google Scholar
• Girroir, E. E. et al. Quantitative expression patterns of peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) protein in mice. Biochem. Biophys. Res. Commun. 371, 456–461 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Leibowitz, M. D. et al. Activation of PPARδ alters lipid metabolism in db/db mice. FEBS Lett. 473, 333–336 (2000). This study was one of the first to demonstrate a functional phenotype resulting from activating PPARβ/δ.
  Article CAS PubMed Google Scholar
• Oliver, W. R. Jr. et al. A selective peroxisome proliferator-activated receptor δ agonist promotes reverse cholesterol transport. Proc. Natl Acad. Sci. USA 98, 5306–5311 (2001).
  Article CAS PubMed PubMed Central Google Scholar
• Sprecher, D. L. et al. Triglyceride:high-density lipoprotein cholesterol effects in healthy subjects administered a peroxisome proliferator activated receptor δ agonist. Arterioscler. Thromb. Vasc. Biol. 27, 359–365 (2007).
  Article CAS PubMed Google Scholar
• Tanaka, T. et al. Activation of peroxisome proliferator-activated receptor δ induces fatty acid β-oxidation in skeletal muscle and attenuates metabolic syndrome. Proc. Natl Acad. Sci. USA 100, 15924–15929 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Wang, Y. X. et al. Peroxisome-proliferator-activated receptor δ activates fat metabolism to prevent obesity. Cell 113, 159–170 (2003).
  Article CAS PubMed Google Scholar
• Wang, Y. X. et al. Regulation of muscle fiber type and running endurance by PPARδ. PLoS Biol. 2, e294 (2004).
  Article PubMed PubMed Central CAS Google Scholar
• Lim, H. J. et al. PPARδ ligand L-165041 ameliorates Western diet-induced hepatic lipid accumulation and inflammation in LDLR−/− mice. Eur. J. Pharmacol. 622, 45–51 (2009).
  Article CAS PubMed Google Scholar
• Liu, S. et al. Role of peroxisome proliferator-activated receptor δ/β in hepatic metabolic regulation. J. Biol. Chem. 286, 1237–1247 (2011).
  Article CAS PubMed Google Scholar
• Nagasawa, T. et al. Effects of bezafibrate, PPAR pan-agonist, and GW501516, PPARδ agonist, on development of steatohepatitis in mice fed a methionine- and choline-deficient diet. Eur. J. Pharmacol. 536, 182–191 (2006).
  Article CAS PubMed Google Scholar
• Shan, W. et al. Peroxisome proliferator-activated receptor-β/δ protects against chemically induced liver toxicity in mice. Hepatology 47, 225–235 (2008).
  Article CAS PubMed Google Scholar
• Shan, W. et al. Ligand activation of peroxisome proliferator-activated receptor β/δ (PPARβ/δ) attenuates carbon tetrachloride hepatotoxicity by downregulating proinflammatory gene expression. Toxicol. Sci. 105, 418–428 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Burdick, A. D., Kim, D. J., Peraza, M. A., Gonzalez, F. J. & Peters, J. M. The role of peroxisome proliferator-activated receptor-β/δ in epithelial cell growth and differentiation. Cell. Signal. 18, 9–20 (2006).
  Article CAS PubMed Google Scholar
• Zhu, Y. et al. Structural organization of mouse peroxisome proliferator-activated receptor γ (mPPARγ) gene: alternative promoter use and different splicing yield two mPPARγ isoforms. Proc. Natl Acad. Sci. USA 92, 7921–7925 (1995).
  Article CAS PubMed PubMed Central Google Scholar
• Fajas, L., Fruchart, J. C. & Auwerx, J. PPARγ3 mRNA: a distinct PPARγ mRNA subtype transcribed from an independent promoter. FEBS Lett. 438, 55–60 (1998).
  Article CAS PubMed Google Scholar
• Foreman, J. E. et al. Regulation of peroxisome proliferator-activated receptor-β/δ by the APC/β-CATENIN pathway and nonsteroidal antiinflammatory drugs. Mol. Carcinog. 48, 942–952 (2009); erratum 50, 652–653 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Abbott, B. D., Wood, C. R., Watkins, A. M., Das, K. P. & Lau, C. S. Peroxisome proliferator-activated receptors α, β, and γ mRNA and protein expression in human fetal tissues. PPAR Res. 2010, 690907 (2010); erratum 2010, 627284 (2010).
  PubMed PubMed Central Google Scholar
• Barak, Y. et al. PPARγ is required for placental, cardiac, and adipose tissue development. Mol. Cell 4, 585–595 (1999).
  Article CAS PubMed Google Scholar
• Tontonoz, P., Hu, E., Graves, R. A., Budavari, A. I. & Spiegelman, B. M. mPPAR γ 2: tissue-specific regulator of an adipocyte enhancer. Genes Dev. 8, 1224–1234 (1994).
  Article CAS PubMed Google Scholar
• Tontonoz, P., Hu, E. & Spiegelman, B. M. Stimulation of adipogenesis in fibroblasts by PPAR γ 2, a lipid-activated transcription factor. Cell 79, 1147–1156 (1994).
  Article CAS PubMed Google Scholar
• Semple, R. K., Chatterjee, V. K. & O'Rahilly, S. PPAR γ and human metabolic disease. J. Clin. Invest. 116, 581–589 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Reddy, J. K., Azarnoff, D. L. & Hignite, C. E. Hypolipidaemic hepatic peroxisome proliferators form a novel class of chemical carcinogens. Nature 283, 397–398 (1980). This study was one of the first to demonstrate that long-term administration of PPARα agonists causes liver cancer in rodents.
  Article CAS PubMed Google Scholar
• Peters, J. M., Cattley, R. C. & Gonzalez, F. J. Role of PPARα in the mechanism of action of the nongenotoxic carcinogen and peroxisome proliferator Wy-14,643. Carcinogenesis 18, 2029–2033 (1997). This study established that PPARα is required to mediate hepatocarcinogenesis caused by long-term administration of PPARα agonists in mice.
  Article CAS PubMed Google Scholar
• Hays, T. et al. Role of peroxisome proliferator-activated receptor-α (PPARα) in bezafibrate-induced hepatocarcinogenesis and cholestasis. Carcinogenesis 26, 219–227 (2005).
  Article CAS PubMed Google Scholar
• Peters, J. M., Cheung, C. & Gonzalez, F. J. Peroxisome proliferator-activated receptor-α and liver cancer: where do we stand? J. Mol. Med. 83, 774–785 (2005).
  Article CAS PubMed Google Scholar
• Cheung, C. et al. Diminished hepatocellular proliferation in mice humanized for the nuclear receptor peroxisome proliferator-activated receptor-α. Cancer Res. 64, 3849–3854 (2004).
  Article CAS PubMed Google Scholar
• Morimura, K., Cheung, C., Ward, J. M., Reddy, J. K. & Gonzalez, F. J. Differential susceptibility of mice humanized for peroxisome proliferator-activated receptor α to Wy-14,643-induced liver tumorigenesis. Carcinogenesis 27, 1074–1080 (2006). This study demonstrated that PPARα-humanized transgenic models do not develop liver tumours after long-term administration of PPARα agonists, suggesting a species difference in activities between human and rodent PPARα.
  Article CAS PubMed Google Scholar
• Shah, Y. M. et al. Peroxisome proliferator-activated receptor α regulates a microRNA-mediated signaling cascade responsible for hepatocellular proliferation. Mol. Cell. Biol. 27, 4238–4247 (2007). This study helped to elucidate the mechanism that explains why human PPARα does not mediate hepatocarcinogenesis, but the mouse PPARα does, by showing differential regulation of let-7c miRNA.
  Article CAS PubMed PubMed Central Google Scholar
• He, T. C., Chan, T. A., Vogelstein, B. & Kinzler, K. W. PPARδ is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell 99, 335–345 (1999).
  Article CAS PubMed PubMed Central Google Scholar
• Modica, S. et al. The intestinal nuclear receptor signature with epithelial localization patterns and expression modulation in tumors. Gastroenterology 138, 636–648 (2010).
  Article CAS PubMed Google Scholar
• Foreman, J. E. et al. Functional characterization of peroxisome proliferator-activated receptor-β/δ expression in colon cancer. Mol. Carcinog. 50, 884–900 (2011). This is the most quantitative study to date showing that expression of PPARβ/δ protein is lower in human and rodent colon tumours compared with non-transformed tissue and also includes functional characterization of overexpression of PPARβ/δ in human colon cancer cell lines.
  Article CAS PubMed PubMed Central Google Scholar
• Delage, B., Rullier, A., Capdepont, M., Rullier, E. & Cassand, P. The effect of body weight on altered expression of nuclear receptors and cyclooxygenase-2 in human colorectal cancers. Nutr. J. 6, 20 (2007).
  Article PubMed PubMed Central CAS Google Scholar
• Gupta, R. A. et al. Prostacyclin-mediated activation of peroxisome proliferator-activated receptor δ in colorectal cancer. Proc. Natl Acad. Sci. USA 97, 13275–13280 (2000).
  Article CAS PubMed PubMed Central Google Scholar
• Roy, H. K., Karolski, W. J. & Ratashak, A. Distal bowel selectivity in the chemoprevention of experimental colon carcinogenesis by the non-steroidal anti-inflammatory drug nabumetone. Int. J. Cancer 92, 609–615 (2001).
  Article CAS PubMed Google Scholar
• Takayama, O. et al. Expression of PPARδ in multistage carcinogenesis of the colorectum: implications of malignant cancer morphology. Br. J. Cancer 95, 889–895 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Wang, D., Ning, W., Xie, D., Guo, L. & Dubois, R. N. Peroxisome proliferator-activated receptor δ confers resistance to peroxisome proliferator-activated receptor γ-induced apoptosis in colorectal cancer cells. Oncogene 18 July 2011 (doi: 10.1038/onc.2011.299).
  Article CAS PubMed PubMed Central Google Scholar
• Yang, L. et al. Biological function and prognostic significance of peroxisome proliferator-activated receptor δ in rectal cancer. Clin. Cancer Res. 17, 3760–3770 (2011). This study provides the strongest clinical evidence to date showing that PPARβ/δ protects against colorectal cancer in humans.
  Article CAS PubMed Google Scholar
• Yoshinaga, M. et al. The simultaneous expression of peroxisome proliferator-activated receptor delta and cyclooxygenase-2 may enhance angiogenesis and tumor venous invasion in tissues of colorectal cancers. Dig. Dis. Sci. 54, 1108–1114 (2009).
  Article CAS PubMed Google Scholar
• Yoshinaga, M. et al. The expression of both peroxisome proliferator-activated receptor δ and cyclooxygenase-2 in tissues is associated with poor prognosis in colorectal cancer patients. Dig. Dis. Sci. 56, 1194–1200 (2011).
  Article CAS PubMed Google Scholar
• Davidson, B., Hadar, R., Stavnes, H. T., Trope, C. G. & Reich, R. Expression of the peroxisome proliferator-activated receptors-α, -β, and -γ in ovarian carcinoma effusions is associated with poor chemoresponse and shorter survival. Hum. Pathol. 40, 705–713 (2009).
  Article CAS PubMed Google Scholar
• Glazer, R. I., Yuan, H., Xie, Z. & Yin, Y. PPARγ and PPARδ as modulators of neoplasia and cell fate. PPAR Res. 2008, 247379 (2008).
  Article PubMed PubMed Central CAS Google Scholar
• Jaeckel, E. C. et al. Correlation of expression of cyclooxygenase-2, vascular endothelial growth factor, and peroxisome proliferator-activated receptor δ with head and neck squamous cell carcinoma. Arch. Otolaryngol. Head Neck Surg. 127, 1253–1259 (2001).
  Article CAS PubMed Google Scholar
• Nijsten, T., Geluyckens, E., Colpaert, C. & Lambert, J. Peroxisome proliferator-activated receptors in squamous cell carcinoma and its precursors. J. Cutan. Pathol. 32, 340–347 (2005).
  Article PubMed Google Scholar
• Tong, B. J. et al. Heightened expression of cyclooxygenase-2 and peroxisome proliferator- activated receptor-δ in human endometrial adenocarcinoma. Neoplasia 2, 483–490 (2000).
  Article CAS PubMed PubMed Central Google Scholar
• Chen, L. C. et al. Alteration of gene expression in normal-appearing colon mucosa of APC(min) mice and human cancer patients. Cancer Res. 64, 3694–3700 (2004).
  Article CAS PubMed Google Scholar
• Hao, C. Y. et al. Alteration of gene expression in macroscopically normal colonic mucosa from individuals with a family history of sporadic colon cancer. Clin. Cancer Res. 11, 1400–1407 (2005).
  Article CAS PubMed Google Scholar
• Harman, F. S. et al. Peroxisome proliferator-activated receptor-δ attenuates colon carcinogenesis. Nature Med. 10, 481–483 (2004).
  Article CAS PubMed Google Scholar
• Knutsen, H. K. et al. Increased levels of PPARβ/δ and cyclin D1 in flat dysplastic ACF and adenomas in _Apc_Min/+ mice. Anticancer Res. 25, 3781–3789 (2005).
  CAS PubMed Google Scholar
• Notterman, D. A., Alon, U., Sierk, A. J. & Levine, A. J. Transcriptional gene expression profiles of colorectal adenoma, adenocarcinoma, and normal tissue examined by oligonucleotide arrays. Cancer Res. 61, 3124–3130 (2001).
  CAS PubMed Google Scholar
• Orner, G. A. et al. Suppression of tumorigenesis in the Apcmin mouse: down-regulation of β-catenin signaling by a combination of tea plus sulindac. Carcinogenesis 24, 263–267 (2003).
  Article CAS PubMed Google Scholar
• Reed, K. R. et al. PPARδ status and Apc-mediated tumourigenesis in the mouse intestine. Oncogene 23, 8992–8996 (2004).
  Article CAS PubMed Google Scholar
• Feilchenfeldt, J., Brundler, M. A., Soravia, C., Totsch, M. & Meier, C. A. Peroxisome proliferator-activated receptors (PPARs) and associated transcription factors in colon cancer: reduced expression of PPARγ-coactivator 1 (PGC-1). Cancer Lett. 203, 25–33 (2004).
  Article CAS PubMed Google Scholar
• Yang, L. et al. Quantitative analysis of PPARδ mRNA by real-time RT-PCR in 86 rectal cancer tissues. Eur. J. Surg. Oncol. 32, 181–185 (2006).
  Article CAS PubMed Google Scholar
• Ahmed, N., Riley, C. & Quinn, M. A. An immunohistochemical perspective of PPARβ and one of its putative targets PDK1 in normal ovaries, benign and malignant ovarian tumours. Br. J. Cancer 98, 1415–1424 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Yoshimura, R. et al. Expression of peroxisome proliferator-activated receptors (PPARs) in human urinary bladder carcinoma and growth inhibition by its agonists. Int. J. Cancer 104, 597–602 (2003).
  Article CAS PubMed Google Scholar
• Foreman, J. E. et al. Regulation of peroxisome proliferator-activated receptor-β/δ by the APC/β-CATENIN pathway and nonsteroidal antiinflammatory drugs. Mol. Carcinog. 48, 942–952 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Ouyang, N., Williams, J. L. & Rigas, B. NO-donating aspirin isomers downregulate peroxisome proliferator-activated receptor (PPAR)δ expression in APC min/+ mice proportionally to their tumor inhibitory effect: implications for the role of PPARδ in carcinogenesis. Carcinogenesis 27, 232–239 (2006).
  Article CAS PubMed Google Scholar
• Fevr, T., Robine, S., Louvard, D. & Huelsken, J. Wnt/β-catenin is essential for intestinal homeostasis and maintenance of intestinal stem cells. Mol. Cell. Biol. 27, 7551–7559 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Sansom, O. J. et al. Loss of Apc in vivo immediately perturbs Wnt signaling, differentiation, and migration. Genes Dev. 18, 1385–1390 (2004).
  Article CAS PubMed PubMed Central Google Scholar
• Sheehan, K. M. et al. The relationship between cyclooxygenase-2 expression and colorectal cancer. JAMA 282, 1254–1257 (1999).
  Article CAS PubMed Google Scholar
• Hollingshead, H. E. et al. Ligand activation of peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) and inhibition of cyclooxygenase 2 (COX2) attenuate colon carcinogenesis through independent signaling mechanisms. Carcinogenesis 29, 169–176 (2008).
  Article CAS PubMed Google Scholar
• Gupta, R. A. et al. Activation of nuclear hormone receptor peroxisome proliferator-activated receptor-δ accelerates intestinal adenoma growth. Nature Med. 10, 245–247 (2004).
  Article CAS PubMed Google Scholar
• Wang, D. et al. Crosstalk between peroxisome proliferator-activated receptor δ and VEGF stimulates cancer progression. Proc. Natl Acad. Sci. USA 103, 19069–19074 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Zuo, X. et al. Targeted genetic disruption of peroxisome proliferator-activated receptor-δ and colonic tumorigenesis. J. Natl Cancer Inst. 101, 762–767 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Bility, M. T. et al. Ligand activation of peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) inhibits chemically-induced skin tumorigenesis. Carcinogenesis 29, 2406–2414 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Bility, M. T., Zhu, B., Kang, B. H., Gonzalez, F. J. & Peters, J. M. Ligand activation of peroxisome proliferator-activated receptor-β/δ and inhibition of cyclooxygenase-2 enhances inhibition of skin tumorigenesis. Toxicol. Sci. 113, 27–36 (2010).
  Article CAS PubMed Google Scholar
• Kim, D. J. et al. Peroxisome proliferator-activated receptor β (δ)-dependent regulation of ubiquitin C expression contributes to attenuation of skin carcinogenesis. J. Biol. Chem. 279, 23719–23727 (2004).
  Article CAS PubMed Google Scholar
• Kim, D. J., Prabhu, K. S., Gonzalez, F. J. & Peters, J. M. Inhibition of chemically-induced skin carcinogenicity by sulindac is independent of peroxisome proliferator-activated receptor-β/δ (PPARβ/δ). Carcinogenesis 27, 1105–1112 (2006).
  Article CAS PubMed Google Scholar
• Zhu, B. et al. Chemoprevention of chemically induced skin tumorigenesis by ligand activation of peroxisome proliferator-activated receptor-β/δ and inhibition of cyclooxygenase 2. Mol. Cancer Ther. 9, 3267–3277 (2011).
  Article CAS Google Scholar
• Di-Poi, N., Tan, N. S., Michalik, L., Wahli, W. & Desvergne, B. Antiapoptotic role of PPARβ in keratinocytes via transcriptional control of the Akt1 signaling pathway. Mol. Cell 10, 721–733 (2002).
  Article CAS PubMed Google Scholar
• Tan, N. S. et al. Critical roles of PPARβ/δ in keratinocyte response to inflammation. Genes Dev. 15, 3263–3277 (2001).
  Article CAS PubMed PubMed Central Google Scholar
• Borland, M. G. et al. Ligand activation of peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) inhibits cell proliferation in human HaCaT keratinocytes. Mol. Pharmacol. 74, 1429–1442 (2008).
  Article CAS PubMed Google Scholar
• Burdick, A. D. et al. Ligand activation of peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) inhibits cell growth of human N/TERT-1 keratinocytes. Cell. Signal. 19, 1163–1171 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Kim, D. J. et al. PPARβ/δ selectively induces differentiation and inhibits cell proliferation. Cell Death Differ. 13, 53–60 (2006).
  Article CAS PubMed Google Scholar
• Narkar, V. A. et al. AMPK and PPARδ agonists are exercise mimetics. Cell 134, 405–415 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Pollock, C. B. et al. PPARδ activation acts cooperatively with 3-phosphoinositide-dependent protein kinase-1 to enhance mammary tumorigenesis. PLoS ONE 6, e16215 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Tachibana, K. et al. Gene expression profiling of potential peroxisome proliferator-activated receptor (PPAR) target genes in human hepatoblastoma cell lines inducibly expressing different PPAR isoforms. Nucl. Recept. 3, 3 (2005).
  Article PubMed PubMed Central CAS Google Scholar
• Szeles, L. et al. Research resource: transcriptome profiling of genes regulated by RXR and its permissive and nonpermissive partners in differentiating monocyte-derived dendritic cells. Mol. Endocrinol. 24, 2218–2231 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Hollingshead, H. E. et al. Peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) ligands do not potentiate growth of human cancer cell lines. Carcinogenesis 28, 2641–2649 (2007).
  Article CAS PubMed Google Scholar
• Schug, T. T., Berry, D. C., Shaw, N. S., Travis, S. N. & Noy, N. Opposing effects of retinoic acid on cell growth result from alternate activation of two different nuclear receptors. Cell 129, 723–733 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Rohrl, C. et al. Peroxisome-proliferator-activated receptors γ and β/δ mediate vascular endothelial growth factor production in colorectal tumor cells. J. Cancer Res. Clin. Oncol. 137, 29–39 (2011).
  Article CAS PubMed Google Scholar
• Stephen, R. L. et al. Activation of peroxisome proliferator-activated receptor δ stimulates the proliferation of human breast and prostate cancer cell lines. Cancer Res. 64, 3162–3170 (2004).
  Article CAS PubMed Google Scholar
• Mantovani, A., Allavena, P., Sica, A. & Balkwill, F. Cancer-related inflammation. Nature 454, 436–444 (2008).
  Article CAS PubMed Google Scholar
• Grommes, C., Landreth, G. E. & Heneka, M. T. Antineoplastic effects of peroxisome proliferator-activated receptor γ agonists. Lancet Oncol. 5, 419–429 (2004).
  Article CAS PubMed Google Scholar
• Koeffler, H. P. Peroxisome proliferator-activated receptor γ and cancers. Clin. Cancer Res. 9, 1–9 (2003).
  CAS PubMed Google Scholar
• Ogino, S. et al. Colorectal cancer expression of peroxisome proliferator-activated receptor γ (PPARG, PPARγ) is associated with good prognosis. Gastroenterology 136, 1242–1250 (2009). This study provided clinical evidence showing that PPARγ protects against colorectal cancer in humans.
  Article CAS PubMed Google Scholar
• McAlpine, C. A., Barak, Y., Matise, I. & Cormier, R. T. Intestinal-specific PPARγ deficiency enhances tumorigenesis in ApcMin/+ mice. Int. J. Cancer 119, 2339–2346 (2006).
  Article CAS PubMed Google Scholar
• Elnemr, A. et al. PPARγ ligand (thiazolidinedione) induces growth arrest and differentiation markers of human pancreatic cancer cells. Int. J. Oncol. 17, 1157–1164 (2000).
  CAS PubMed Google Scholar
• Gupta, R. A., Brockman, J. A., Sarraf, P., Willson, T. M. & DuBois, R. N. Target genes of peroxisome proliferator-activated receptor γ in colorectal cancer cells. J. Biol. Chem. 276, 29681–29687 (2001).
  Article CAS PubMed Google Scholar
• Sarraf, P. et al. Differentiation and reversal of malignant changes in colon cancer through PPARγ. Nature Med. 4, 1046–1052 (1998).
  Article CAS PubMed Google Scholar
• Tontonoz, P. et al. Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor γ and the retinoid X receptor. Proc. Natl Acad. Sci. USA 94, 237–241 (1997). This study was one of the first to establish that PPARγ ligands can induce differentiation in human cancer cells providing support for the hypothesis that targeting PPARγ may be suitable for human cancers.
  Article CAS PubMed PubMed Central Google Scholar
• Yoshizumi, T. et al. Thiazolidinedione, a peroxisome proliferator-activated receptor-γ ligand, inhibits growth and metastasis of HT-29 human colon cancer cells through differentiation-promoting effects. Int. J. Oncol. 25, 631–639 (2004).
  CAS PubMed Google Scholar
• Drori, S. et al. Hic-5 regulates an epithelial program mediated by PPARγ. Genes Dev. 19, 362–375 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Huang, J. W. et al. Peroxisome proliferator-activated receptor γ-independent ablation of cyclin D1 by thiazolidinediones and their derivatives in breast cancer cells. Mol. Pharmacol. 67, 1342–1348 (2005).
  Article CAS PubMed Google Scholar
• Lapillonne, H. et al. Activation of peroxisome proliferator-activated receptor γ by a novel synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid induces growth arrest and apoptosis in breast cancer cells. Cancer Res. 63, 5926–5939 (2003).
  CAS PubMed Google Scholar
• Qin, C. et al. Peroxisome proliferator-activated receptor γ agonists induce proteasome-dependent degradation of cyclin D1 and estrogen receptor α in MCF-7 breast cancer cells. Cancer Res. 63, 958–964 (2003).
  CAS PubMed Google Scholar
• Wang, C. et al. Inhibition of cellular proliferation through IκB kinase-independent and peroxisome proliferator-activated receptor γ-dependent repression of cyclin D1. Mol. Cell. Biol. 21, 3057–3070 (2001).
  Article CAS PubMed PubMed Central Google Scholar
• Yin, F. et al. Troglitazone inhibits growth of MCF-7 breast carcinoma cells by targeting G1 cell cycle regulators. Biochem. Biophys. Res. Commun. 286, 916–922 (2001).
  Article CAS PubMed Google Scholar
• Koga, H. et al. Involvement of p21WAF1/Cip1, p27Kip1, and p18INK4c in troglitazone-induced cell-cycle arrest in human hepatoma cell lines. Hepatology 33, 1087–1097 (2001).
  Article CAS PubMed Google Scholar
• Chen, F. & Harrison, L. E. Ciglitazone-induced cellular anti-proliferation increases p27kip1 protein levels through both increased transcriptional activity and inhibition of proteasome degradation. Cell. Signal. 17, 809–816 (2005).
  Article CAS PubMed Google Scholar
• Chen, F., Kim, E., Wang, C. C. & Harrison, L. E. Ciglitazone-induced p27 gene transcriptional activity is mediated through Sp1 and is negatively regulated by the MAPK signaling pathway. Cell. Signal. 17, 1572–1577 (2005).
  Article CAS PubMed Google Scholar
• Itami, A. et al. Ligands for peroxisome proliferator-activated receptor γ inhibit growth of pancreatic cancers both in vitro and in vivo. Int. J. Cancer 94, 370–376 (2001).
  Article CAS PubMed Google Scholar
• Koga, H. et al. Troglitazone induces p27_Kip1_-associated cell-cycle arrest through down-regulating Skp2 in human hepatoma cells. Hepatology 37, 1086–1096 (2003).
  Article CAS PubMed Google Scholar
• Motomura, W., Okumura, T., Takahashi, N., Obara, T. & Kohgo, Y. Activation of peroxisome proliferator-activated receptor γ by troglitazone inhibits cell growth through the increase of p27KiP1 in human. Pancreatic carcinoma cells. Cancer Res. 60, 5558–5564 (2000).
  CAS PubMed Google Scholar
• Sharma, C., Pradeep, A., Wong, L., Rana, A. & Rana, B. Peroxisome proliferator-activated receptor γ activation can regulate β-catenin levels via a proteasome-mediated and adenomatous polyposis coli-independent pathway. J. Biol. Chem. 279, 35583–35594 (2004).
  Article CAS PubMed Google Scholar
• Wei, S. et al. Thiazolidinediones modulate the expression of β-catenin and other cell-cycle regulatory proteins by targeting the F-box proteins of Skp1-Cul1-F-box protein E3 ubiquitin ligase independently of peroxisome proliferator-activated receptor γ. Mol. Pharmacol. 72, 725–733 (2007).
  Article CAS PubMed Google Scholar
• Palakurthi, S. S., Aktas, H., Grubissich, L. M., Mortensen, R. M. & Halperin, J. A. Anticancer effects of thiazolidinediones are independent of peroxisome proliferator-activated receptor γ and mediated by inhibition of translation initiation. Cancer Res. 61, 6213–6218 (2001).
  CAS PubMed Google Scholar
• Bae, M. A. & Song, B. J. Critical role of c-Jun N-terminal protein kinase activation in troglitazone-induced apoptosis of human HepG2 hepatoma cells. Mol. Pharmacol. 63, 401–408 (2003).
  Article CAS PubMed Google Scholar
• Zander, T. et al. Induction of apoptosis in human and rat glioma by agonists of the nuclear receptor PPARγ. J. Neurochem. 81, 1052–1060 (2002).
  Article CAS PubMed Google Scholar
• Shiau, C. W. et al. Thiazolidenediones mediate apoptosis in prostate cancer cells in part through inhibition of Bcl-xL/Bcl-2 functions independently of PPARγ. Cancer Res. 65, 1561–1569 (2005).
  Article CAS PubMed Google Scholar
• Farrow, B. & Evers, B. M. Activation of PPARγ increases PTEN expression in pancreatic cancer cells. Biochem. Biophys. Res. Commun. 301, 50–53 (2003).
  Article CAS PubMed Google Scholar
• Lee, S. Y. et al. PPAR-γ agonist increase gefitinib's antitumor activity through PTEN expression. Lung Cancer 51, 297–301 (2006).
  Article PubMed Google Scholar
• Patel, L. et al. Tumor suppressor and anti-inflammatory actions of PPARγ agonists are mediated via upregulation of PTEN. Curr. Biol. 11, 764–768 (2001).
  Article CAS PubMed Google Scholar
• Teresi, R. E. et al. Increased PTEN expression due to transcriptional activation of PPARγ by Lovastatin and Rosiglitazone. Int. J. Cancer 118, 2390–2398 (2006).
  Article CAS PubMed Google Scholar
• Zhang, W. et al. PPARγ activator rosiglitazone inhibits cell migration via upregulation of PTEN in human hepatocarcinoma cell line BEL-7404. Cancer Biol. Ther. 5, 1008–1014 (2006).
  Article CAS PubMed Google Scholar
• Kim, K. Y., Kim, S. S. & Cheon, H. G. Differential anti-proliferative actions of peroxisome proliferator-activated receptor-γ agonists in MCF-7 breast cancer cells. Biochem. Pharmacol. 72, 530–540 (2006).
  Article CAS PubMed Google Scholar
• Yan, K. H. et al. The synergistic anticancer effect of troglitazone combined with aspirin causes cell cycle arrest and apoptosis in human lung cancer cells. Mol. Carcinog. 49, 235–246 (2010).
  Article CAS PubMed Google Scholar
• Kim, Y., Suh, N., Sporn, M. & Reed, J. C. An inducible pathway for degradation of FLIP protein sensitizes tumor cells to TRAIL-induced apoptosis. J. Biol. Chem. 277, 22320–22329 (2002).
  Article CAS PubMed Google Scholar
• Schultze, K. et al. Troglitazone sensitizes tumor cells to TRAIL-induced apoptosis via down-regulation of FLIP and Survivin. Apoptosis 11, 1503–1512 (2006).
  Article CAS PubMed Google Scholar
• Wei, S., Yang, J., Lee, S. L., Kulp, S. K. & Chen, C. S. PPARγ-independent antitumor effects of thiazolidinediones. Cancer Lett. 276, 119–124 (2009).
  Article CAS PubMed Google Scholar
• Glass, C. K. & Saijo, K. Nuclear receptor transrepression pathways that regulate inflammation in macrophages and T cells. Nature Rev. Immunol. 10, 365–376 (2010).
  Article CAS Google Scholar
• Adachi, M. et al. Peroxisome proliferator activated receptor γ in colonic epithelial cells protects against experimental inflammatory bowel disease. Gut 55, 1104–1113 (2006). This study demonstrated that PPARγ inhibits inflammation in the gut and protects against inflammatory bowel, which may explain in part the protective nature of PPARγ in colorectal cancer.
  Article CAS PubMed PubMed Central Google Scholar
• Shah, Y. M., Morimura, K. & Gonzalez, F. J. Expression of peroxisome proliferator-activated receptor-γ in macrophage suppresses experimentally induced colitis. Am. J. Physiol. Gastrointest. Liver Physiol. 292, G657–G666 (2007).
  Article CAS PubMed Google Scholar
• Greten, F. R. et al. IKKβ links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 118, 285–296 (2004).
  Article CAS PubMed Google Scholar
• Lefebvre, A. M. et al. Activation of the peroxisome proliferator-activated receptor γ promotes the development of colon tumors in C57BL/6J-APC_Min_/+ mice. Nature Med. 4, 1053–1057 (1998).
  Article CAS PubMed Google Scholar
• Saez, E. et al. Activators of the nuclear receptor PPARγ enhance colon polyp formation. Nature Med. 4, 1058–1061 (1998).
  Article CAS PubMed Google Scholar
• Pino, M. V., Kelley, M. F. & Jayyosi, Z. Promotion of colon tumors in C57BL/6J-APCmin/+ mice by thiazolidinedione PPARγ agonists and a structurally unrelated PPARγ agonist. Toxicol. Pathol. 32, 58–63 (2004).
  Article CAS PubMed Google Scholar
• Yang, K. et al. Peroxisome proliferator-activated receptor γ agonist troglitazone induces colon tumors in normal C57BL/6J mice and enhances colonic carcinogenesis in _Apc_1638 N/+Mlh1+/− double mutant mice. Int. J. Cancer 116, 495–499 (2005).
  Article CAS PubMed Google Scholar
• Lubet, R. A. et al. Rosiglitazone, a PPARγ agonist: potent promoter of hydroxybutyl(butyl)nitrosamine-induced urinary bladder cancers. Int. J. Cancer 123, 2254–2259 (2008).
  Article CAS PubMed Google Scholar
• Piccinni, C., Motola, D., Marchesini, G. & Poluzzi, E. Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting. Diabetes Care 34, 1369–1371 (2011).
  Article PubMed PubMed Central Google Scholar
• Fenner, M. H. & Elstner, E. Peroxisome proliferator-activated receptor-γ ligands for the treatment of breast cancer. Expert Opin. Investig. Drugs 14, 557–568 (2005).
  Article CAS PubMed Google Scholar
• Saez, E. et al. PPARγ signaling exacerbates mammary gland tumor development. Genes Dev. 18, 528–540 (2004).
  Article CAS PubMed PubMed Central Google Scholar
• Li, Y. & Lazar, M. A. Differential gene regulation by PPARγ agonist and constitutively active PPARγ2. Mol. Endocrinol. 16, 1040–1048 (2002).
  CAS PubMed Google Scholar
• Panigrahy, D. et al. PPARα agonist fenofibrate suppresses tumor growth through direct and indirect angiogenesis inhibition. Proc. Natl Acad. Sci. USA 105, 985–990 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Pozzi, A. et al. Peroxisomal proliferator-activated receptor-α-dependent inhibition of endothelial cell proliferation and tumorigenesis. J. Biol. Chem. 282, 17685–17695 (2007).
  Article CAS PubMed Google Scholar
• Balkwill, F. TNF-α in promotion and progression of cancer. Cancer Metastasis Rev. 25, 409–416 (2006).
  Article CAS PubMed Google Scholar
• Aoyama, A. et al. Altered constitutive expression of fatty acid-metabolizing enzymes in mice lacking the peroxisome proliferator-activated receptor α (PPARα). J. Biol. Chem. 273, 5678–5684 (1998).
  Article CAS PubMed Google Scholar
• Koppenol, W. H., Bounds, P. L. & Dang, C. V. Otto Warburg's contributions to current concepts of cancer metabolism. Nature Rev. Cancer 11, 325–337 (2011).
  Article CAS Google Scholar
• Tsugane, S. & Inoue, M. Insulin resistance and cancer: epidemiological evidence. Cancer Sci. 101, 1073–1079 (2010).
  Article CAS PubMed Google Scholar
• Wolin, K. Y., Carson, K. & Colditz, G. A. Obesity and cancer. Oncologist 15, 556–565 (2011).
  Article Google Scholar
• Kasuga, J. et al. Novel biphenylcarboxylic acid peroxisome proliferator-activated receptor (PPAR) δ selective antagonists. Bioorg. Med. Chem. Lett. 19, 6595–6599 (2009).
  Article CAS PubMed Google Scholar
• Naruhn, S. et al. High affinity peroxisome proliferator-activated receptor β/δ-specific ligands with pure antagonistic or inverse agonistic properties. Mol. Pharmacol. 80, 828–838 (2011).
  Article CAS PubMed Google Scholar
• Shearer, B. G. et al. Identification and characterization of a selective peroxisome proliferator-activated receptor β/δ (NR1C2) antagonist. Mol. Endocrinol. 22, 523–529 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Shearer, B. G. et al. Identification and characterization of 4-chloro-_N_-(2-{[5-trifluoromethyl)-2-pyridyl]sulfonyl}ethyl)benzamide (GSK3787), a selective and irreversible peroxisome proliferator-activated receptor δ (PPARδ) antagonist. J. Med. Chem. 53, 1857–1861 (2010).
  Article CAS PubMed Google Scholar
• Zaveri, N. T. et al. A novel peroxisome proliferator-activated receptor δ antagonist, SR13904, has anti-proliferative activity in human cancer cells. Cancer Biol. Ther. 8, 1252–1261 (2009).
  Article CAS PubMed Google Scholar
• Palkar, P. S. et al. Cellular and pharmacological selectivity of the PPARβ/δ antagonist GSK3787. Mol. Pharmacol. 78, 419–430 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Demetri, G. D. & et al. Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-γ ligand troglitazone in patients with liposarcoma. Proc. Natl Acad. Sci. USA 96, 3951–3956 (1999).
  Article CAS PubMed PubMed Central Google Scholar
• Debrock, G. et al. A phase II trial with rosiglitazone in liposarcoma patients. Br. J. Cancer 89, 1409–1412 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Smith, M. R. et al. Rosiglitazone versus placebo for men with prostate carcinoma and a rising serum prostate-specific antigen level after radical prostatectomy and/or radiation therapy. Cancer 101, 1569–1574 (2004).
  Article CAS PubMed Google Scholar
• Hisatake, J. I. et al. Down-regulation of prostate-specific antigen expression by ligands for peroxisome proliferator-activated receptor γ in human prostate cancer. Cancer Res. 60, 5494–5498 (2000).
  CAS PubMed Google Scholar
• Mueller, E. et al. Effects of ligand activation of peroxisome proliferator-activated receptor γ in human prostate cancer. Proc. Natl Acad. Sci. USA 97, 10990–10995 (2000).
  Article CAS PubMed PubMed Central Google Scholar
• Schwartz, G. K. et al. Phase I and pharmacokinetic study of LY293111, an orally bioavailable LTB4 receptor antagonist, in patients with advanced solid tumors. J. Clin. Oncol. 23, 5365–5373 (2005).
  Article CAS PubMed Google Scholar
• Burstein, H. J. et al. Use of the peroxisome proliferator-activated receptor (PPAR) γ ligand troglitazone as treatment for refractory breast cancer: a phase II study. Breast Cancer Res. Treat. 79, 391–397 (2003).
  Article CAS PubMed Google Scholar
• Kulke, M. H. et al. A phase II study of troglitazone, an activator of the PPARγ receptor, in patients with chemotherapy-resistant metastatic colorectal cancer. Cancer J. 8, 395–399 (2002).
  Article PubMed Google Scholar
• Baetz, T. et al. A phase I study of oral LY293111 given daily in combination with irinotecan in patients with solid tumours. Invest. New Drugs 25, 217–225 (2007).
  Article CAS PubMed Google Scholar
• Read, W. L., Baggstrom, M. Q., Fracasso, P. M. & Govindan, R. A phase I study of bexarotene and rosiglitazone in patients with refractory cancers. Chemotherapy 54, 236–241 (2008).
  Article CAS PubMed Google Scholar
• Hau, P. et al. Low-dose chemotherapy in combination with COX-2 inhibitors and PPAR-γ agonists in recurrent high-grade gliomas - a phase II study. Oncology 73, 21–25 (2007).
  Article CAS PubMed Google Scholar
• Kebebew, E. et al. A phase II trial of rosiglitazone in patients with thyroglobulin-positive and radioiodine-negative differentiated thyroid cancer. Surgery 140, 960–966; discussion 966–967 (2006).
  Article PubMed Google Scholar
• Tepmongkol, S., Keelawat, S., Honsawek, S. & Ruangvejvorachai, P. Rosiglitazone effect on radioiodine uptake in thyroid carcinoma patients with high thyroglobulin but negative total body scan: a correlation with the expression of peroxisome proliferator-activated receptor-γ. Thyroid 18, 697–704 (2008).
  Article CAS PubMed Google Scholar
• Kroll, T. G. et al. PAX8-PPARγ1 fusion oncogene in human thyroid carcinoma. Science 289, 1357–1360 (2000).
  Article CAS PubMed Google Scholar
• Giordano, T. J. et al. Delineation, functional validation, and bioinformatic evaluation of gene expression in thyroid follicular carcinomas with the PAX8-PPARG translocation. Clin. Cancer Res. 12, 1983–1993 (2006).
  Article CAS PubMed Google Scholar
• Lacroix, L. et al. Follicular thyroid tumors with the PAX8-PPARγ1 rearrangement display characteristic genetic alterations. Am. J. Pathol. 167, 223–231 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Erdmann, E., Charbonnel, B. & Wilcox, R. Thiazolidinediones and cardiovascular risk - a question of balance. Curr. Cardiol. Rev. 5, 155–165 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Grey, A. et al. The peroxisome proliferator-activated receptor-γ agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial. J. Clin. Endocrinol. Metab. 92, 1305–1310 (2007).
  Article CAS PubMed Google Scholar
• Kahn, S. E. et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N. Engl. J. Med. 355, 2427–2443 (2006).
  Article CAS PubMed Google Scholar
• Schwartz, A. V. & Sellmeyer, D. E. Thiazolidinedione therapy gets complicated: is bone loss the price of improved insulin resistance? Diabetes Care 30, 1670–1671 (2007).
  Article CAS PubMed Google Scholar
• Schwartz, A. V. et al. Thiazolidinedione use and bone loss in older diabetic adults. J. Clin. Endocrinol. Metab. 91, 3349–3354 (2006).
  Article CAS PubMed Google Scholar
• Kodera, Y. et al. Ligand type-specific interactions of peroxisome proliferator-activated receptor γ with transcriptional coactivators. J. Biol. Chem. 275, 33201–33204 (2000).
  Article CAS PubMed Google Scholar
• Zhang, Q., Zhou, H., Zhai, S. & Yan, B. Natural product-inspired synthesis of thiazolidine and thiazolidinone compounds and their anticancer activities. Curr. Pharm. Des. 16, 1826–1842 (2010).
  Article CAS PubMed Google Scholar
• Burton, J. D., Castillo, M. E., Goldenberg, D. M. & Blumenthal, R. D. Peroxisome proliferator-activated receptor-γ antagonists exhibit potent antiproliferative effects versus many hematopoietic and epithelial cancer cell lines. Anticancer Drugs 18, 525–534 (2007).
  Article CAS PubMed Google Scholar
• Lea, M. A., Sura, M. & Desbordes, C. Inhibition of cell proliferation by potential peroxisome proliferator-activated receptor (PPAR) γ agonists and antagonists. Anticancer Res. 24, 2765–2771 (2004).
  CAS PubMed Google Scholar
• Schaefer, K. L. et al. Peroxisome proliferator-activated receptor γ inhibition prevents adhesion to the extracellular matrix and induces anoikis in hepatocellular carcinoma cells. Cancer Res. 65, 2251–2259 (2005).
  Article CAS PubMed Google Scholar
• Takahashi, H. et al. Inhibition of peroxisome proliferator-activated receptor γ activity in esophageal carcinoma cells results in a drastic decrease of invasive properties. Cancer Sci. 97, 854–860 (2006).
  Article CAS PubMed Google Scholar
• Burton, J. D., Goldenberg, D. M. & Blumenthal, R. D. Potential of peroxisome proliferator-activated receptor γ antagonist compounds as therapeutic agents for a wide range of cancer types. PPAR Res. 2008, 494161 (2008).
  Article PubMed PubMed Central CAS Google Scholar
• Osborne, C. K. et al. Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer. J. Natl Cancer Inst. 87, 746–750 (1995).
  Article CAS PubMed Google Scholar
• Kohno, H., Suzuki, R., Sugie, S. & Tanaka, T. Suppression of colitis-related mouse colon carcinogenesis by a COX-2 inhibitor and PPAR ligands. BMC Cancer 5, 46 (2005).
  Article PubMed PubMed Central CAS Google Scholar
• Niho, N. et al. Concomitant suppression of hyperlipidemia and intestinal polyp formation in Apc-deficient mice by peroxisome proliferator-activated receptor ligands. Cancer Res. 63, 6090–6095 (2003).
  CAS PubMed Google Scholar
• Tanaka, T. et al. Ligands for peroxisome proliferator-activated receptors α and γ inhibit chemically induced colitis and formation of aberrant crypt foci in rats. Cancer Res. 61, 2424–2428 (2001).
  CAS PubMed Google Scholar
• Tenenbaum, A. et al. Does the lipid-lowering peroxisome proliferator-activated receptors ligand bezafibrate prevent colon cancer in patients with coronary artery disease? Cardiovasc. Diabetol. 7, 18 (2008). This study suggests that the pan-PPAR agonist bezafibrate may prevent colon cancer in humans, supporting the hypothesis that targeting all three PPARs may be suitable for chemoprevention.
  Article PubMed PubMed Central CAS Google Scholar
• Jackson, L. et al. Potential role for peroxisome proliferator activated receptor (PPAR) in preventing colon cancer. Gut 52, 1317–1322 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Khanim, F. L. et al. Combined bezafibrate and medroxyprogesterone acetate: potential novel therapy for acute myeloid leukaemia. PLoS ONE 4, e8147 (2009).
  Article PubMed PubMed Central CAS Google Scholar
• Hayden, R. E. et al. Treatment of primary CLL cells with bezafibrate and medroxyprogesterone acetate induces apoptosis and represses the pro-proliferative signal of CD40-ligand, in part through increased 15dΔ12,14, PGJ2 . Leukemia 23, 292–304 (2009).
  Article CAS PubMed Google Scholar
• Rubenstrunk, A., Hanf, R., Hum., D. W., Fruchart, J. C. & Staels, B. Safety issues and prospects for future generations of PPAR modulators. Biochim. Biophys. Acta 1771, 1065–1081 (2007).
  Article CAS PubMed Google Scholar
• Peraza, M. A., Burdick, A. D., Marin, H. E., Gonzalez, F. J. & Peters, J. M. The toxicology of ligands for peroxisome proliferator-activated receptors (PPAR). Toxicol. Sci. 90, 269–295 (2006).
  Article CAS PubMed Google Scholar
• Still, K., Grabowski, P., Mackie, I., Perry, M. & Bishop, N. The peroxisome proliferator activator receptor α/δ agonists linoleic acid and bezafibrate upregulate osteoblast differentiation and induce periosteal bone formation in vivo. Calcif. Tissue Int. 83, 285–292 (2008).
  Article CAS PubMed Google Scholar
• Brautigam, K. et al. Combined treatment with TRAIL and PPARγ ligands overcomes chemoresistance of ovarian cancer cell lines. J. Cancer Res. Clin. Oncol. 137, 875–886 (2011).
  Article CAS PubMed Google Scholar
• Cesario, R. M., Stone, J., Yen, W. C., Bissonnette, R. P. & Lamph, W. W. Differentiation and growth inhibition mediated via the RXR:PPARγ heterodimer in colon cancer. Cancer Lett. 240, 225–233 (2006).
  Article CAS PubMed Google Scholar
• Crowe, D. L. & Chandraratna, R. A. A retinoid X receptor (RXR)-selective retinoid reveals that RXR-α is potentially a therapeutic target in breast cancer cell lines, and that it potentiates antiproliferative and apoptotic responses to peroxisome proliferator-activated receptor ligands. Breast Cancer Res. 6, R546–R555 (2004).
  Article CAS PubMed PubMed Central Google Scholar
• Desreumaux, P. et al. Attenuation of colon inflammation through activators of the retinoid X receptor (RXR)/peroxisome proliferator-activated receptor γ (PPARγ) heterodimer. A basis for new therapeutic strategies. J. Exp. Med. 193, 827–838 (2001).
  Article CAS PubMed PubMed Central Google Scholar
• Fu, H. et al. Chemoprevention of lung carcinogenesis by the combination of aerosolized budesonide and oral pioglitazone in A/J. mice. Mol. Carcinog. 50, 913–921 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Girnun, G. D. et al. Synergy between PPARγ ligands and platinum-based drugs in cancer. Cancer Cell 11, 395–406 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Hamaguchi, N. et al. In vitro and in vivo therapeutic efficacy of the PPAR-γ agonist troglitazone in combination with cisplatin against malignant pleural mesothelioma cell growth. Cancer Sci. 101, 1955–1964 (2010).
  Article CAS PubMed Google Scholar
• Park, B. H., Lee, S. B., Stolz, D. B., Lee, Y. J. & Lee, B. C. Synergistic interactions between heregulin and peroxisome proliferator-activated receptor-γ (PPARγ) agonist in breast cancer cells. J. Biol. Chem. 286, 20087–20099 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Reddy, R. C. et al. Chemotherapeutic drugs induce PPARγ expression and show sequence-specific synergy with PPARγ ligands in inhibition of non-small cell lung cancer. Neoplasia 10, 597–603 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Tikoo, K., Kumar, P. & Gupta, J. Rosiglitazone synergizes anticancer activity of cisplatin and reduces its nephrotoxicity in 7, 12-dimethyl benz{a}anthracene (DMBA) induced breast cancer rats. BMC Cancer 9, 107 (2009).
  Article PubMed PubMed Central CAS Google Scholar
• Yamazaki, K. et al. Synergistic effects of RXR α and PPAR γ ligands to inhibit growth in human colon cancer cells--phosphorylated RXR α is a critical target for colon cancer management. Gut 56, 1557–1563 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Yokoyama, Y., Xin, B., Shigeto, T. & Mizunuma, H. Combination of ciglitazone, a peroxisome proliferator-activated receptor γ ligand, and cisplatin enhances the inhibition of growth of human ovarian cancers. J. Cancer Res. Clin. Oncol. 137, 1219–1228 (2011).
  Article CAS PubMed Google Scholar
• Fauconnet, S. et al. Differential regulation of vascular endothelial growth factor expression by peroxisome proliferator-activated receptors in bladder cancer cells. J. Biol. Chem. 277, 23534–23543 (2002).
  Article CAS PubMed Google Scholar
• Meissner, M., Hrgovic, I., Doll, M. & Kaufmann, R. PPARδ agonists suppress angiogenesis in a VEGFR2-dependent manner. Arch. Dermatol. Res. 303, 41–47 (2011).
  Article CAS PubMed Google Scholar
• Abdollahi, A. et al. Transcriptional network governing the angiogenic switch in human pancreatic cancer. Proc. Natl Acad. Sci. USA 104, 12890–12895 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Müller-Brüsselbach, S. et al. Deregulation of tumor angiogenesis and blockade of tumor growth in PPARβ-deficient mice. EMBO J. 26, 3686–3698 (2007).
  Article PubMed PubMed Central CAS Google Scholar
• Piqueras, L. et al. Activation of PPARβ/δ induces endothelial cell proliferation and angiogenesis. Arterioscler. Thromb. Vasc. Biol. 27, 63–69 (2007).
  Article CAS PubMed Google Scholar
• Biscetti, F. et al. Selective activation of peroxisome proliferator-activated receptor (PPAR)α and PPARγ induces neoangiogenesis through a vascular endothelial growth factor-dependent mechanism. Diabetes 57, 1394–1404 (2008).
  Article CAS PubMed Google Scholar
• Bishop-Bailey, D. & Hla, T. Endothelial cell apoptosis induced by the peroxisome proliferator-activated receptor (PPAR) ligand 15-deoxy-Δ12,14-prostaglandin J2 . J. Biol. Chem. 274, 17042–17048 (1999).
  Article CAS PubMed Google Scholar
• Chu, K. et al. Peroxisome proliferator-activated receptor-γ-agonist, rosiglitazone, promotes angiogenesis after focal cerebral ischemia. Brain Res. 1093, 208–218 (2006).
  Article CAS PubMed Google Scholar
• Huang, P. H. et al. Pioglitazone ameliorates endothelial dysfunction and restores ischemia-induced angiogenesis in diabetic mice. Biomed. Pharmacother. 62, 46–52 (2008).
  Article CAS PubMed Google Scholar
• Xin, X., Yang, S., Kowalski, J. & Gerritsen, M. E. Peroxisome proliferator-activated receptor γ ligands are potent inhibitors of angiogenesis in vitro and in vivo. J. Biol. Chem. 274, 9116–9121 (1999).
  Article CAS PubMed Google Scholar
• Chintalgattu, V., Harris, G. S., Akula, S. M. & Katwa, L. C. PPAR-γ agonists induce the expression of VEGF and its receptors in cultured cardiac myofibroblasts. Cardiovasc. Res. 74, 140–150 (2007).
  Article CAS PubMed Google Scholar